A Real‐World Study of CGRP Monoclonal Antibodies for Migraine: Long‐Term Effectiveness and Treatment Adherence
European Journal of Neurology · 2026-03 · 33 (3)
DOI: 10.1111/ene.70562 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 09.03.2026. Verfasst von Keisuke Suzuki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dokkyo Medical University, Mibu, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are effective for migraine prophylaxis; however, real‐world evidence beyond 1 year remains limited.
Methods
This single‐center, retrospective observational cohort study in Japan included 307 migraine patients who received CGRP mAbs (erenumab, galcanezumab, or fremanezumab) for ≥ 3 months between April 2022 and February 2025 for an effectiveness analysis. Outcomes included monthly migraine days (MMDs), ≥ 50% responder rates, adverse events (AEs), and treatment persistence. Patients were categorized as nonresponders or responders: early (≥ 50% MMD reduction by Month 3), late (Months 4–5), and ultralate (after Month 6).
Results
Significant MMD reductions were observed across 24 months. The ≥ 50% response rates were 45.9%, 57.0%, 63.6%, and 71.0% at 3, 6, 12, and 24 months, respectively. AEs occurred in 12.6% and were mild. Early responders had the lowest baseline MMDs and Migraine Disability Assessment (MIDAS) scores; nonresponders had the highest baseline MMDs and MIDAS scores and the highest rates of comorbid medication overuse headache (MOH) and psychiatric disorders. Compared with early responders, late and ultralate responders had higher baseline MMDs, higher MIDAS scores, higher rates of MOH, and more prior preventive failures. Additionally, ultralate responders presented the highest rates of photophobia and pulsatile headache and the fewest psychiatric comorbidities. Effectiveness appeared similar among the three CGRP mAbs. Treatment continuation rates were 68.3%, 58.0%, and 50.6% at 12, 18, and 24 months, respectively.
Conclusion
CGRP mAbs were associated with a long‐term reduction in migraine frequency and favorable tolerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Dokkyo Medical University, Mibu, Japan.
- Department of Public Health, Dokkyo Medical University School of Medicine, Mibu, Japan.
ORCID-Profile: Keisuke Suzuki, Saro Kobayashi, Hiroaki Fujita
Zitieren
APA
Suzuki, K., Suzuki, S., Kobayashi, S., Shioda, M., Fujita, H., Haruyama, Y., & Hirata, K. (2026). A Real‐World Study of CGRP Monoclonal Antibodies for Migraine: Long‐Term Effectiveness and Treatment Adherence. European Journal of Neurology, 33(3). https://doi.org/10.1111/ene.70562
Vancouver
Suzuki K, Suzuki S, Kobayashi S, Shioda M, Fujita H, Haruyama Y, et al. A Real‐World Study of CGRP Monoclonal Antibodies for Migraine: Long‐Term Effectiveness and Treatment Adherence. European Journal of Neurology. 2026;33(3). doi:10.1111/ene.70562
BibTeX
@article{Suzuki2026,
author = {Suzuki, Keisuke and Suzuki, Shiho and Kobayashi, Saro and Shioda, Mukuto and Fujita, Hiroaki and Haruyama, Yasuo and Hirata, Koichi},
title = {A Real‐World Study of CGRP Monoclonal Antibodies for Migraine: Long‐Term Effectiveness and Treatment Adherence},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {3},
doi = {10.1111/ene.70562}
}
EUVIMED